Mink Therapeutics (INKT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually, with voting available online, by phone, mail, or during the meeting.
Stockholders as of April 23, 2026, are eligible to vote on director elections and auditor ratification.
Proxy materials are distributed via internet access, with options for printed copies and electronic delivery to reduce environmental impact.
A one-for-ten reverse stock split was effected on January 28, 2025.
Voting matters and shareholder proposals
Election of three Class II directors (Garo Armen, Barbara Ryan, John Holcomb) for three-year terms expiring at the 2029 annual meeting.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting FOR all nominees and auditor ratification.
Shareholders may submit proposals for the 2027 annual meeting by December 30, 2026, following specific procedures.
Board of directors and corporate governance
Board consists of seven members divided into three classes, with annual elections for one class.
Majority of directors are independent; annual self-evaluations and performance assessments are conducted.
Three standing committees: Audit and Finance, Compensation, and Corporate Governance and Nominating; an Affiliate Transactions Committee addresses conflicts with Agenus.
Code of Ethics and Securities Trading Policy updated in 2023; independent directors meet in executive session.
Latest events from Mink Therapeutics
- Durable clinical results, strong cash position, and major trial milestones expected in 2026.INKT
Q4 202531 Mar 2026 - Net loss narrowed, cash increased, and iNKT pipeline advanced, but funding risks remain.INKT
Q2 20241 Feb 2026 - iNKT cell therapies show promise in hard-to-treat cancers and ARDS, with pivotal trials underway.INKT
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Net loss narrowed, cash burn fell, and clinical progress continues amid funding risks.INKT
Q3 202414 Jan 2026 - Net loss narrowed and clinical pipeline advanced, supporting growth and cash runway into 2025.INKT
Q4 202425 Dec 2025 - Biotech seeks up to $150M for iNKT cell therapy R&D, with ongoing losses and dilution risks.INKT
Registration Filing16 Dec 2025 - Biotech registers 4.64M shares for resale; lead iNKT therapy in Phase 2, no proceeds to company.INKT
Registration Filing16 Dec 2025 - Biotech seeks $150M for iNKT cell therapy R&D, facing losses and dilution risk.INKT
Registration Filing16 Dec 2025 - Key votes include director elections, an option exchange, and auditor ratification.INKT
Proxy Filing2 Dec 2025